Circulation
.
2004;110(11):1484-1491.
20. Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene
delivery technology based on chemical methods and nano-
carriers.
Theranostics
. 2014;4(3):240-255.
doi:10.7150/thno.6914.
21. Fang B, Roth JA. Tumor-suppressing gene therapy.
Cancer Biol
Ther
. 2003;2(4,Suppl.1):S115-S121.
22. Roth JA. Adenovirus p53 gene therapy.
Expert Opin Biol Ther.
2006;6:55-61.
23. Peng Z. Current status of gendicine in China: recombinant Ad-
p53 agent for treatment of cancers.
Hum Gene Ther.
2005;16:1016-
1027.
24. Fung H, Gersson S. Viral insertion site detection and analysis
in cancer gene therapy. In: Lattime EC, Gerson SL, eds.
Gene
therapy of cancer.
3rd ed. San Diego (CA): Elsevier; 2013:35-46.
25. Gujrati M, Lu Z. Targeted systemic delivery of therapeutic
siRNA. In: Lattime EC, Gerson SL, eds.
Gene therapy of cancer.
3rd ed. San Diego (CA): Elsevier; 2013:47-65.
26. Davis ME. The first targeted delivery of siRNA in humans via a
self-assembling, cyclodextrin polymer-based nanoparticle: from
concept to clinic.
Mol Pharm
. 2009;6(3):659-668.
doi:10.1021/mp900015y.
27. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A,
Schwartz GK, Weiss GJ et al. First-in-humans trial of an RNA
interference therapeutic targeting VEGF and KSP in cancer
patients with liver involvement.
Cancer Discov
. 2013;3:406-417.
doi:10.1158/2159-8290.CD-12-0429.
28. Freeman SM, Whartenby KA, Freeman JL, Abboud CN,
Marrogi AJ. In situ use of suicide genes for cancer therapy.
Semin
Oncol
. 1996;23:31-45.
29. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V.
Suicide gene therapy in cancer: Where do we stand now?
Cancer
Lett
. 2012;324(2):160-170.
doi:10.1016/j.canlet.2012.05.023.
30. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A,
Vanninen R et al. AdvHSV-tk gene therapy with intravenous
ganciclovir improves survival in human malignant glioma: a
randomized, controlled study.
Mol Ther
. 2004;10(5):967-972.
31. van Putten EH, Dirven CM, van den Bent MJ, Lamfers ML.
Sitimagene ceradenovec: a gene-based drug for the treatment of
operable high-grade glioma.
Future Oncol
. 2010;6(11):1691-1610.
doi:10.2217/fon.10.134.
32. Aghi M, Martuza RL. Oncolytic viral therapies — the clinical
expirience.
Oncogene
. 2005;24:7802-7816.
33. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R,
Kirn D. Efficacy of a replication-selective adenovirus against
ovarian carcinomatosis is dependent on tumor burden, viral
replication and p53 status.
Gene Ther
. 2000;7:1925-1929.
34. Available at: http://www.oncolyticsbiotech.com/clinical.html
35. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et
al. A phase I study of OncoVEXGM-CSF, a second-generation
oncolytic herpes simplex virus expressing granulocyte macrophage
colony-stimulating factor.
Clin Cancer Res
. 2006;12(22):6737-
6747.
36. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG,
Schlom J. A triad of costimulatory molecules synergize to amplify
T-cell activation.
Cancer Res
. 1999;59:5800-5807.
37. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine
combination therapy to enhance induction of immune responses
to a self-antigen and antitumor activity.
Cancer Res
. 2002;62:5770-
5777.
38. Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L,
Schlom J. Modified vaccinia virus ankara recombinants are as
potent as vaccinia recombinants in diversified prime and boost
vaccine regimens to elicit therapeutic antitumor responses.
Cancer
Res
. 2003;63:7942-7949.
39. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM,
Bilhartz DL, Wyand M et al. Overall survival analysis of a phase
II randomized controlled trial of a Poxviral-based PSA-targeted
immunotherapy in metastatic castration-resistant prostate cancer.
J Clin Oncol
. 2010;28:1099-1105.
doi:10.1200/JCO.2009.25.0597.
40. Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK. Interim
analysis of a phase 2 randomized clinical trial of samarium-153
(Sm-153) with or without PSA-TRICOM vaccine in metastatic
castration-resistant prostate cancer after docetaxel.
J Clin Oncol.
2012;30(15,Suppl.):abstr.2526. (ASCO Annual Meeting. June
1-5, Chicago; 2012.)
41. Docetaxel alone or in combination with vaccine to treat breast
cancer. Docetaxel and prednisone with or without vaccine therapy
ОНКОЛОГИЯ. ЖУРНАЛ им. П.А. ГЕРЦЕНА, 2, 2016
72
in treating patients with metastatic hormone-resistant prostate
cancer. Available at: http://www.clinicaltrials.gov/
42. Turtle CJ. Chimeric antigen receptor modified T cell therapy for
B cell malignancies.
Int J Hematol
. 2014;99(2):132-140.
doi:10.1007/s12185-013-1490-x.
43. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O et
al. Closely related T-memory stem cells correlate with in vivo
expansion of CAR.CD19-T cells and are preserved by IL-7 and
IL-15.
Blood
. 2014;123(24):3750-3759.
doi:10.1182/blood-2014-01-552174.
44. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner
DE, Maric I et al. B-cell depletion and remissions of malignancy
along with cytokine-associated toxicity in a clinical trial of anti-
CD19 chimeric-antigen-receptor-transduced T cells.
Blood
.
2012;119(12):2709-2720.
doi:10.1182/blood-2011-10-384388.
45. Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-
modified cells for adoptive cell therapy of cancer.
Expert Opin Biol
Ther.
2014;14(7):947-954.
doi:10.1517/14712598.2014.900540.
46. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa
M. Gene medicine for cancer treatment: Commercially avail-
able medicine and accumulated clinical data in
China Dev Ther
.
2008;2:115-122.
47. Wierzbicki AS, Viljoen A. Alipogene tiparvovec: gene therapy for
lipoprotein lipase deficiency.
Expert Opin Biol Ther
. 2013;13(1):7-
10.
doi:10.1517/14712598.2013.738663.
48. Деев Р.В. Генная терапия в России: три года опыта. Химия и
жизнь-XXI век. 2013;12. Доступно по: http://www.hij.ru
49. Доступно по: http://www.dissercat.com/content/strategiya-
sozdaniya-tselnokletochnykh-antimelanomnykh-vaktsin
50. Вдовиченко Г.В., Петрищенко В.А., Сергеев А.А., Ким И.И.,
Фатюхина О.Е., Шишкина Л.Н. и др. Доклинические иссле-
дования противоракового лечебного аденовирусного препа-
рата «канцеролизин».
Вопросы вирусологии
. 2006;51(6):39-42.
51. Немцова Е.Р., Безбородова О.А., Кармакова Т.А., Якубов-
ская Р.И. Инновационный геннотерапевтический препарат
АдеЛакт: детоксицирующее действие и биораспределение в
организме животных рекомбинантного лактоферрина чело-
века.
Биофармацевтический журнал
. 2013;5(6):42-51.
52. Alekseenko IV, Chernov IP, Potapov VK, Monastyrskaya GS,
Bezborodova OA, Plyutinskaya AD et al. Therapeutic properties
of a vector carrying the HSV thymidine kinase and GM-CSF
genes and delivered as a complex with a cationic copolymer.
J
Transl Med
. 2015;13(1):78-89.
doi:10.1186/s12967-015-0433-0.
Поступила 26.10.2015
Читайте в следующем номере:
●
Видеоэндоскопическая хирургия в лечении больных начальным раком
яичников
●
Возможности интраоперационной ультразвуковой диагностики при раке
яичников
●
Результаты хирургического лечения больных немелкоклеточным раком
легкого с прорастанием опухоли в грудную стенку
ОБЗОРЫ ЛИТЕРАТУРЫ
Достарыңызбен бөлісу: |